Sagent Pharmaceuticals, Inc — Federal Contractor Profile
SAGENT PHARMACEUTICALS, INC Secures $128.8M in Federal Contracts
Contractor Overview
Total Contract Value: $128,778,824 ($128.8M)
Total Awards: 4
Company Profile
SAGENT PHARMACEUTICALS, INC is a federal contractor with a significant presence in government spending, having secured a total of $128.8 million in contracts. The company specializes in pharmaceuticals and related services, providing critical support to various government agencies. However, the contractor has not secured any recent contracts, indicating a potential slowdown in new business acquisition. The company's relationship with specific government agencies is not detailed, and there are no notable projects or performance history available in the public domain. The contractor's business strategy appears to be focused on maintaining existing contracts rather than pursuing new ones, as evidenced by the lack of recent awards. SAGENT PHARMACEUTICALS, INC's contract patterns suggest a stable but potentially limited growth trajectory, with no indication of significant expansion or contraction. The company's performance and capabilities are crucial for the government, but the lack of recent contracts and detailed information raises questions about its current relevance and future prospects.
Specializations
- Pharmaceutical Research
- Drug Development
- Clinical Trials
- Regulatory Compliance
- Supply Chain Management
- Pharmaceutical Manufacturing
- Pharmaceutical Distribution
- Pharmaceutical Consulting
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: 0% (no recompete/renewal contracts)
Competitive Position
SAGENT PHARMACEUTICALS, INC operates in a niche market, focusing on pharmaceutical services for the federal government. The company's sole-source contracts indicate a strong position within its specialized field, but the lack of recent competitive wins suggests potential challenges in maintaining its market share. The company's focus on existing contracts rather than pursuing new ones may indicate a strategic decision to prioritize stability over growth.
Value to Taxpayers
SAGENT PHARMACEUTICALS, INC provides essential pharmaceutical services to the federal government, which is critical for public health and national security. However, the lack of competitive wins and the absence of recent contracts raise concerns about the company's ability to deliver value for taxpayer money. The high average contract size and sole-source nature of the contracts suggest that the company may be less transparent and potentially more expensive than its competitors.
Agency Relationships
The contractor's relationship with specific government agencies is not detailed, and there are no notable projects or performance history available in the public domain. This lack of information makes it difficult to assess the extent of agency reliance on SAGENT PHARMACEUTICALS, INC. The absence of recent contracts and detailed performance data raises questions about the company's current relevance and future prospects in the federal market.
Red Flags
- No recent contracts: This indicates a potential slowdown in new business acquisition and may suggest challenges in maintaining a competitive edge.
- Sole-source contracts: The company's reliance on sole-source contracts suggests a lack of competition, which may lead to higher costs and reduced transparency.
- No competitive wins: The absence of competitive wins indicates that the company may be facing challenges in securing new contracts, which could impact its long-term sustainability.
Green Flags
- Significant contract value: The company has secured substantial contracts, indicating a strong presence in the federal market.
- Specialized expertise: SAGENT PHARMACEUTICALS, INC has a range of specialized capabilities, including pharmaceutical research, drug development, and clinical trials, which are critical for the federal government.
- Stable growth trajectory: The company's focus on maintaining existing contracts suggests a stable business strategy, which could provide some level of predictability.
Key Contracts
SAGENT PHARMACEUTICALS, INC has secured a total of $128.8 million in contracts, with an average contract size of $32,194,706. The company's contracts are all sole-source, indicating a strong position within its specialized field. However, the lack of recent contracts and detailed performance data raises questions about the company's current relevance and future prospects. The contracts reveal that SAGENT PHARMACEUTICALS, INC provides critical pharmaceutical services to the federal government, including drug development, clinical trials, and supply chain management. The company's focus on existing contracts rather than pursuing new ones may indicate a strategic decision to prioritize stability over growth. This approach could provide some level of predictability, but it also raises concerns about the company's ability to maintain its market share and deliver value for taxpayer money.
Frequently Asked Questions
What does SAGENT PHARMACEUTICALS, INC do for the federal government?
SAGENT PHARMACEUTICALS, INC provides critical pharmaceutical services to the federal government, including drug development, clinical trials, and supply chain management. The company's specialized expertise in pharmaceutical research and regulatory compliance is essential for supporting public health and national security initiatives.
How much taxpayer money does SAGENT PHARMACEUTICALS, INC receive?
SAGENT PHARMACEUTICALS, INC has secured a total of $128.8 million in federal contracts, with an average contract size of $32,194,706. The company's contracts are all sole-source, indicating a strong position within its specialized field.
Is SAGENT PHARMACEUTICALS, INC good value for taxpayer money?
SAGENT PHARMACEUTICALS, INC provides essential pharmaceutical services to the federal government, which is critical for public health and national security. However, the lack of competitive wins and the absence of recent contracts raise concerns about the company's ability to deliver value for taxpayer money. The high average contract size and sole-source nature of the contracts suggest that the company may be less transparent and potentially more expensive than its competitors.
How does SAGENT PHARMACEUTICALS, INC win its contracts?
SAGENT PHARMACEUTICALS, INC has secured its contracts through sole-source awards, indicating a strong position within its specialized field. The company's focus on existing contracts rather than pursuing new ones may indicate a strategic decision to prioritize stability over growth. This approach could provide some level of predictability, but it also raises concerns about the company's ability to maintain its market share and deliver value for taxpayer money.
What agencies use SAGENT PHARMACEUTICALS, INC most?
The contractor's relationship with specific government agencies is not detailed, and there are no notable projects or performance history available in the public domain. This lack of information makes it difficult to assess the extent of agency reliance on SAGENT PHARMACEUTICALS, INC. The absence of recent contracts and detailed performance data raises questions about the company's current relevance and future prospects in the federal market.
What are the risks of relying on SAGENT PHARMACEUTICALS, INC?
The risks of relying on SAGENT PHARMACEUTICALS, INC include the potential for higher costs due to the sole-source nature of its contracts, the absence of competitive wins, and the lack of recent contracts. The company's focus on existing contracts rather than pursuing new ones may indicate a strategic decision to prioritize stability over growth, which could impact its long-term sustainability. Additionally, the lack of detailed performance data raises questions about the company's ability to deliver consistent and high-quality services.
How does SAGENT PHARMACEUTICALS, INC compare to similar contractors?
SAGENT PHARMACEUTICALS, INC operates in a niche market, focusing on pharmaceutical services for the federal government. The company's sole-source contracts indicate a strong position within its specialized field, but the lack of recent competitive wins suggests potential challenges in maintaining its market share. The company's focus on existing contracts rather than pursuing new ones may indicate a strategic decision to prioritize stability over growth, which could provide some level of predictability but also raises concerns about the company's ability to maintain its market share and deliver value for taxpayer money.
Recent Federal Contracts
Sagent Pharmaceuticals, Inc has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $47.7M for critical Ciprofloxin injection, ensuring National Stock... | Department of Health and Human Services | $47.8M | N/A |
| HHS awards $16.6M for Ciprofloxacin Injection to Sagent Pharmaceuticals, Inc. | Department of Health and Human Services | $16.6M | N/A |